Your session is about to expire
← Back to Search
Other
Emetine for COVID-19 (EVOLVE Trial)
Phase 2 & 3
Waitlist Available
Led By Kunchok Dorjee, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
30 years of age or older at time of randomization
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 30, 90 and 180 after medication administration up to day 180.
Awards & highlights
EVOLVE Trial Summary
This trial will evaluate if Emetine can help treat Covid-19 and if it is safe. Participants take meds, monitored for symptoms, and have blood drawn.
Who is the study for?
This trial is for people over 30 with symptomatic COVID-19 confirmed by RT-PCR within the last 10 days. Participants must have had symptoms like cough, fever, or sore throat in the past week and be able to consent. It's not for asymptomatic patients, those in other trials, critically ill patients, pregnant women, or those with heart disease.Check my eligibility
What is being tested?
The EVOLVE trial is testing if Emetine Hydrochloride (6mg taken orally for 10 days) can improve COVID-19 symptoms compared to a placebo. Patients will self-monitor or be monitored daily and undergo blood tests to track their progress.See study design
What are the potential side effects?
Potential side effects of Emetine may include nausea, vomiting, stomach upset, fatigue and rarely cardiac issues such as irregular heartbeat; however specific side effects related to this trial are not listed.
EVOLVE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 30 years old or older.
EVOLVE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ days 30, 90 and 180 after medication administration up to day 180.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 30, 90 and 180 after medication administration up to day 180.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Evaluate effectiveness of emetine in symptomatic Covid-19 patients
Evaluate safety of emetine in symptomatic Covid-19 patients
Secondary outcome measures
Anti-inflammatory effect of emetine
Virologic conversion as assessed by SARS-CoV-2 real time polymerase chain reaction (RT-PCR)
Other outcome measures
Determine longer term impact of Covid-19 as assessed by the Health-related quality of life assessment (HR-QOL-14)
EVOLVE Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: EmetineActive Control1 Intervention
Participant takes Emetine 6mg for 10 consecutive days
Group II: PlaceboPlacebo Group1 Intervention
Participant takes a placebo for 10 consecutive days
Find a Location
Who is running the clinical trial?
Nepal Health Research CouncilOTHER_GOV
13 Previous Clinical Trials
5,780 Total Patients Enrolled
4 Trials studying COVID-19
3,326 Patients Enrolled for COVID-19
Stony Brook UniversityOTHER
215 Previous Clinical Trials
39,327 Total Patients Enrolled
3 Trials studying COVID-19
582 Patients Enrolled for COVID-19
Rutgers UniversityOTHER
113 Previous Clinical Trials
2,803,493 Total Patients Enrolled
2 Trials studying COVID-19
944 Patients Enrolled for COVID-19
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I require a breathing tube, mechanical breathing support, or intensive care.I am critically ill with COVID-19.You tested positive for COVID-19 using a specific test within 10 days before the screening visit.I am currently using or have recently used the study drug.I have COVID-19 but do not show any symptoms.I have COVID-19 symptoms like cough, fever, or sore throat, confirmed by a test.I have a history of heart disease or heart rhythm problems.I am 30 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Emetine
- Group 2: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is enrollment in this research program still available?
"Clinicaltrials.gov indicates that this trial, which was initially posted on July 15th 2023 and last updated May 23rd 2023, is no longer enrolling patients. However, there are currently 840 other medical studies actively recruiting participants at this time."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger